Table 1.
Current screening methods and guidelines for colorectal cancer
| Method | Sensitivity | Interval | Society |
| Fecal tests | |||
| FOBT | Yearly | USPSTF, ASGE, | |
| USMSTF | |||
| FIT | 65.8%[32,33] | Yearly | |
| Fecal DNA | 50%-60%[34] | Unspecified | USMSTF |
| Serum markers | |||
| CEA | 30%[35] | ||
| CA19-9 | |||
| Imaging tests | |||
| DCBE | 85%-97%[36] | Every 5 years | USMSTF |
| CTC | 55%-94%[37] | Every 5 years | USMSTF |
| Optical tests | |||
| FS | Every 5 years | USPSTF, ASGE, USMSTF | |
| Every 10 years | |||
| FC | USPSTF, ASGE, USMSTF |
FOBT: Fecal occult blood test; FIT: Fecal immunochemical based stool tests; CEA: Carcinoembryonic antigen; DCBE: Double-contrast barium enema; CTC: Computed tomography colonography; FS: Flexible sigmoidoscopy; FC: Flexible colonoscopy; USPSTF: United States Preventive Services Task Force; ASGE: American Society for Gastrointestinal Endoscopy; USMSTF: Multi-Society Task Force on Colorectal Cancer.